Food And Drug Safety Administration (FDA), US, has approved phase 1 human trial of the first potential Zika virus antidote. Named GLS-5700, the antidote releases genetic agents into the body that are similar to the Zika virus and thus prepares the body’s immune system against Zika. The testing on animals were successful hence the green light has been shone for testing on human volunteers. For the first phase, the antidote will be applied on healthy humans without Zika infection.
The antidote has been created by Inovio Pharmaceuticals. During the testing on humans, the drug will be tested for its potential against Zika and its dosage will be finalised. If successful, second phase of trials will involve patients affected by Zika virus. So far there is no antidote for Zika virus. While it does not kill people, it can cause serious birth defects such as Microcephally among unborn children. Results of the testing will be available by the end of this year.